$SLGL

H.C. Wainwright reiterated a Buy rating and $110 price target for Sol-Gel Technologies (SLGL), citing the upcoming Phase 3 trial data for SGT-610, its lead drug candidate. The stock has risen 84% in the past year to $78.95, with a market cap of $258 million. The trial aims to prevent new basal cell carcinoma lesions in Gorlin syndrome patients, with potential FDA submission in 2027 and approval in late 2027. InvestingPro analysis suggests the stock may be overvalued.

Opaleye Management Inc. purchased 3,124 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $66.39 ($65.94–$66.80, $0.21M total) across 2 trades over 2026-09-10 to 2026-09-11.

Opaleye Management Inc. purchased 9,976 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $68.88 ($68.70–$69.52, $0.69M total) across 5 trades over 2026-09-04 to 2026-09-09.

Opaleye Management Inc. purchased 1,683 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $69.21 ($68.95–$69.52, $0.12M total) across 2 trades over 2026-09-01 to 2026-09-02.

Opaleye Management Inc. purchased 40,330 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $69.19 ($68.24–$71.40, $2.79M total) across 5 trades over 2026-08-28 to 2026-08-31.

Sol-Gel Technologies Ltd. (SLGL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 • So

Opaleye Management Inc. purchased 951 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at $71.50 on 2026-08-12.

Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.

Opaleye Management Inc. purchased 1,695 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.64 ($73.43–$73.89, $0.12M total) across 2 trades over 2026-07-13 to 2026-07-14.

Opaleye Management Inc. purchased 529 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $73.80 ($73.69–$73.95) across 2 trades over 2026-07-08 to 2026-07-10.